Effects of the GIP/GLP-1 receptor agonist Tirzepatide on the cardiovascular system
10.3969/j.issn.1006-6187.2024.09.016
- VernacularTitle:葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽1受体激动剂Tirzepatide对心血管系统作用的研究进展
- Author:
Yingying LUO
1
;
Guangyu WU
;
Linong JI
Author Information
1. 100044 北京大学人民医院内分泌科
- Keywords:
Tirzepatide;
GIP/GLP-1 receptor agonist;
Cardiovascular disease
- From:
Chinese Journal of Diabetes
2024;32(9):715-720
- CountryChina
- Language:Chinese
-
Abstract:
Tirzepatide,the first and currently the only approved GIP/GLP-1 receptor agonist worldwide,has demonstrated favorable effects in glycemic control and body weight reduction in several studies.In recent years,the effects of Tirzepatide on improving cardiovascular risk factors have gained increasing attentions.This article reviews the research progress of the effects of Tirzepatide on the cardiovascular system.
